**CellMosaic, Inc.**
10A Roessler Road
Woburn, MA 01801, USA
Phone: 781-463-0002; Fax: 781-998-4694; E-mail: info@cellmosaic.com

**BSA-SN38 Conjugate**
Lyophilized powder, 1 mg per vial,
≥99% conjugates by SEC HPLC

Product Number: **CM52149**




**Product Description**

SN38, the active metabolite of irinotecan, is a chemotherapeutic agent primarily used in the treatment of colorectal cancer. As a topoisomerase I inhibitor, SN38 interferes with the enzyme responsible for DNA replication, ultimately inducing cancer cell death. This BSA-SN38 conjugate is designed using linker chemistry similar to that of ADC/PDC, which is produced by our customer using CellMosaic's SN38 Conjugation Kits (Cat#: CM11408, CM11430). It is synthesized at CellMosaic and is intended for use in immunization or immunoassay applications. The final conjugate is lyophilized from phosphate-buffered saline for convenient shipping, storage, and reconstitution.

The product is sold as 1 vial of 1 mg (Cat# CM52149-1MG) or 5 vials of 1 mg (Cat# CM52149-5MG). For bulk orders, please contact us for a quote.

**Application**

- Assay development for detection of SN38 or SN38 metabolites in vitro or in vivo.
- Antibody discovery via immunization and hapten recognition
- Indirect and competitive ELISA assay

**Key Features**

- Lyophilized powder and ready for usage after reconstitution with water, no need for external buffer
- Optimized loading with an average 3 to 5 SN38 molecules per BSA
- Amount accurately determined by UV/HPLC analysis

**Storage/Stability**

- Recommended storage of the product is below -20 °C
- Expiration before defrosting is 1 year after receiving
- Once defrosted maintain at 2-8 °C
- For best quality use within 1 week of defrosting

**Selected References for SN38 and SN38-BSA**

1) Qing-rui Qi, et al. Research Progress of SN38 Drug Delivery System in Cancer Treatment. Int J Nanomedicine. 2024 Jan 26;19:945–964.
2) Hsin-Che Lin, et al. High Potency of SN-38-Loaded Bovine Serum Albumin Nanoparticles Against Triple-Negative Breast Cancer. Pharmaceutics. 2019 Nov 1;11(11):569.